Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

10.1245/s10434-007-9612-4
Annals of Surgical Oncology 15:21-33 (2008)
© 2008 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fatouros, M.
Right arrow Articles by Roukos, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fatouros, M.
Right arrow Articles by Roukos, D. H.

Original Article

The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations

Michael Fatouros, MD, Georgios Baltoyiannis, MD and Dimitrios H. Roukos, MD

Department of Surgery, Ioannina University School of Medicine, 45110, Ioannina, Greece

Correspondence: Address correspondence and reprint requests to: Dimitrios H. Roukos, MD; E-mail: droukos{at}cc.uoi.gr

Background: Advances in understanding molecular and genetic mechanisms underlying cancer promise an "individualized" management of the disease. Women with a BRCA1 or BRCA2 germ-line mutation are at very high risk of breast and/or ovarian cancer. Because high-quality data are lacking from randomized trials, prevention strategies and treatment of patients with BRCA-associated breast cancer are complex.

Methods: The data for this review were obtained by searching PubMed and Medline for articles about optimizing prevention and treating women with familial susceptibility to breast and ovarian cancer.

Results: Prophylactic surgery is the rational approach for women who carry the BRCA mutation; chemoprevention and/or intensified surveillance represent alternative approaches. Prophylactic bilateral salpingo-oophorectomy is superior to bilateral prophylactic mastectomy. However, reaching a definitive clinical decision is complex, and several variables should be considered for an individualized approach. Accumulating data support the concept of more extensive surgery for newly diagnosed breast cancer in women with a BRCA mutation but new unbaised studies are needed for an evidence-based approach . Such patients treated with breast conservation therapy for early-stage breast cancer are at higher risk of contralateral breast cancer than noncarriers. Primary bilateral mastectomy could also be considered and discussed with these patients. Breast tumors from BRCA1 mutation carriers are predominantly of basal subtype (i.e., triple negative), and BRCA2 mutation carriers are of luminal subtype (i.e., estrogen receptor positive). Decisions on adjuvant treatment are based on estrogen receptor, progesterone receptor, and HER2 status.

Conclusions: The complex management of healthy women and breast cancer patients with familial susceptibility to breast and ovarian cancer requires an individualized prevention or treatment strategy by an experienced team.

Key Words: BRCA • Hereditary breast ovarian cancer • Prophylactic surgery • Chemoprevention • Screening • Treatment




This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
G. Zografos and D. H. Roukos
International Randomized Trials' Attention to Locoregional Breast Cancer Control and Promise of Personal Genomics and Whole-Genome Scans for Personalized Approaches
Ann. Surg. Oncol., January 1, 2009; 16(1): 222 - 225.
[Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
E. Fatourou, A. Macheras, E. P. Misiakos, and T. Liakakos
Perioperative Chemotherapy for Gastric Cancer
Ann. Surg. Oncol., January 1, 2009; 16(1): 226 - 227.
[Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
D. Ziogas, E. Ignatiadou, D. Roukos, and E. Lykoudis
HER2 and Trastuzumab: Impact of a New Standard Agent on Local Control and Surgery for Breast Cancer
Ann. Surg. Oncol., December 1, 2008; 15(12): 3614 - 3615.
[Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
E. Ignatiadou, D. Ziogas, E. Lykoudis, E. P. Misiakos, and T. Liakakos
Screening for or Prevention of Local Ipsilateral Recurrence and Contralateral Breast Cancer After Breast-Conserving Surgery?
Ann. Surg. Oncol., December 1, 2008; 15(12): 3617 - 3619.
[Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
T. Liakakos
Benefits and Harms in Avoiding Axilla Lymphadenectomy in Breast Cancer
Ann. Surg. Oncol., October 1, 2008; 15(10): 2978 - 2979.
[Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
T. Liakakos, E. Fatourou, D. Ziogas, E. Lykoudis, and D. H. Roukos
Targeting VEGF, EGFR, and Other Interacting Pathways for Gastric Cancer--Promises and Reality
Ann. Surg. Oncol., October 1, 2008; 15(10): 2981 - 2982.
[Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
T. Liakakos and E. Fatourou
Stage-Specific Guided Adjuvant Treatment for Gastric Cancer
Ann. Surg. Oncol., September 1, 2008; 15(9): 2622 - 2623.
[Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
D. Ziogas and T. Liakakos
Lessons from Laparoscopic Gastrectomy: Preventing Surgical Complications
Ann. Surg. Oncol., September 1, 2008; 15(9): 2624 - 2625.
[Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
D. Ziogas, P. Tsekeris, and E. Fatourou
Benefits, Limitations, and Harm of Local Excision for Rectal Cancer
Ann. Surg. Oncol., September 1, 2008; 15(9): 2628 - 2629.
[Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
D. Ziogas, E. Ignatiadou, and M. Fatouros
Lumpectomy and Partial Breast Irradiation - Risks and Benefits for Early Breast Cancer
Ann. Surg. Oncol., August 1, 2008; 15(8): 2352 - 2353.
[Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
T. Liakakos
Minimal Residual Disease in Breast Cancer: Can It Be Used as a Prognostic Marker?
Ann. Surg. Oncol., June 1, 2008; 15(6): 1793 - 1794.
[Full Text] [PDF]


Home page
JCOHome page
E. Briasoulis and D. H. Roukos
Contralateral Prophylactic Mastectomy: Mind the Genetics
J. Clin. Oncol., April 10, 2008; 26(11): 1909 - 1910.
[Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
H. Harissis and M. Fatouros
Nodal Micrometastases Status--Will It Influence Decisions on Surgical and Adjuvant Treatment for Breast Cancer?
Ann. Surg. Oncol., April 1, 2008; 15(4): 1256 - 1257.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society of Surgical Oncology.